Results 261 to 270 of about 175,639 (315)

5-Fluorouracil and Derivatives in Cancer Chemotherapy: Determination of 5-Fluorouracil in Blood

Journal of Pharmaceutical Sciences, 1972
The current work describes a dialysis technique which separates 5-fluorouracil from interfering blood components and allows for subsequent GC determinations. The parameters affecting the dialysis and GC are presented. The results indicate that 5-fluorouracil is present in the free and bound states in blood, and the method is capable of distinguishing ...
J J, Windheuser, J L, Sutter, E, Auen
openaire   +2 more sources

5-Fluorouracil rechallenge after 5-fluorouracil-induced hyperammonemic encephalopathy

Anti-Cancer Drugs, 2019
For several decades, 5-Fluorouracil (5-FU) has been the backbone of many chemotherapy regimens for various tumor types. Its most common side effects are gastrointestinal disorders, mucositis, myelosuppression, hand-foot syndrome, and rarely cardiac toxicity. More rarely, 5-FU infusion can induce hyperammonemic encephalopathy.
Alice, Boilève, Camille, Wicker, Benjamin, Verret, Florence, Leroy, David, Malka, Mathieu, Jozwiak, Clément, Pontoizeau, Chris, Ottolenghi, Pascale, De Lonlay, Michel, Ducreux, Antoine, Hollebecque   +10 more
openaire   +2 more sources

Trabeculectomy With Intraoperative 5-Fluorouracil

Ophthalmic Surgery, Lasers and Imaging Retina, 1998
* BACKGROUND AND OBJECTIVE: To investigate the outcome and complication rates of trabeculectomy following the combined use of intraoperative, topical 5-fluorouracil (5-FU) and low-dose, postoperative subconjunctival 5-FU injections. * PATIENTS AND METHODS: Forty-one eyes of 41 patients with advanced, medically uncontrolled glaucoma underwent ...
P A, Sidoti, J C, Choi, E N, Morinelli, P P, Lee, G, Baerveldt, D S, Minckler, D K, Heuer   +6 more
openaire   +2 more sources

5-Fluorouracil for glaucoma surgery

Cochrane Database of Systematic Reviews, 2014
Trabeculectomy is performed as a treatment for many types of glaucoma in an attempt to lower the intraocular pressure. The surgery involves creating a channel through the sclera, through which intraocular fluid can leave the eye. If scar tissue blocks the exit of the surgically created channel, intraocular pressure rises and the operation fails ...
Elspeth, Green, Mark, Wilkins, Catey, Bunce, Richard, Wormald   +3 more
openaire   +2 more sources

5-Fluorouracil and dihydropyrimidine dehydrogenase

International Journal of Clinical Oncology, 2003
Dihydropyrimidine dehydrogenase (DPD) is a rate-limiting enzyme of (fluorinated) pyrimidine degradation that plays a significant role in the pharmacokinetics of 5-fluorouracil (5-FU). In addition, a catabolite of 5-FU induces a certain toxicity, and the sensitivity of 5-FU is determined by DPD activity in tumors. DPD is thus important clinically. Drugs
openaire   +3 more sources

Clinical Pharmacology of 5-Fluorouracil

Clinical Pharmacokinetics, 1989
5-Fluorouracil, first introduced as a rationally synthesized anticancer agent 30 years ago, continues to be widely used in the management of several common malignancies including cancer of the colon, breast and skin. This drug, an analogue of the naturally occurring pyrimidine uracil, is metabolised via the same metabolic pathways as uracil.
R B, Diasio, B E, Harris
openaire   +2 more sources

Clinical Cardiotoxicity of 5‐Fluorouracil

The Journal of Clinical Pharmacology, 1993
5‐Fluorouracil is widely known to be toxic to the hematopoietic and gastrointestinal systems. It also has cardiac toxicity, but this is perceived to be rare. During a 16‐month period from January 1990 through April 1991, approximately 910 patients were treated with 5‐fluorouracil.
D L, Keefe, N, Roistacher, M K, Pierri
openaire   +2 more sources

Niosomal delivery of 5-fluorouracil

Journal of Microencapsulation, 1999
Non-ionic surfactant vesicles (niosomes) have shown promise as cheap, chemically stable alternatives to liposomes. Niosomes of spans (Sorbitan monoesters) have shown promise of commercial exploitation. Hence, niosomes were prepared of 5-fluorouracil (FU) using different spans.
A, Namdeo, N K, Jain
openaire   +2 more sources

5-Fluorouracil

2000
Abstract 5-Fluorouracil (FU) is a fluorinated pyrimidine; it is a white crystalline powder, sparingly soluble in water, with a MW of 130.08. This antimetabolite and antineoplastic agent was initially introduced more than 30 years ago; it is used for palliative treatment of colorectal, metastatic breast, ovarian, and skin cancers, and ...
openaire   +1 more source

5-Fluorouracil Metabolizing Enzymes

2003
The uracil analog 5-fluorouracil (5-FU) is used as part of combination therapy for the treatment of breast, head/neck, and gastrointestinal malignancies, and has single-agent activity in colorectal cancer. 5-FU itself is inactive and requires intracellular conversion to form cytotoxic nucleotides (1). Several cellular targets for fluoropyrimidines have
H L, McLeod, L H, Milne, S J, Johnston
openaire   +2 more sources